94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Gustaf Lindgren1,2
Sebastian Ols1,2
Frank Liang1,2
Elizabeth A. Thompson1,2
Ang Lin1,2
Fredrika Hellgren1,2
Kapil Bahl3Shinu John3
Olga Yuzhakov3
Kimberly J. Hassett3
Luis A. Brito4
Hugh Salter4,5Giuseppe Ciaramella3
Karin Loré1,2*- 1Department of Medicine Solna, Immunology and Allergy Unit, Karolinska Institutet, Stockholm, Sweden
- 2Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden
- 3Valera LLC, Cambridge, MA, United States
- 4Moderna Therapeutics, Cambridge, MA, United States
- 5Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
by Lindgren, G., Ols, S., Liang, F., Thompson, E. A., Lin, A., Hellgren, F., et al. (2017). Front. Immunol. 8:1539. doi: 10.3389/fimmu.2017.01539
In the original article, Liang et al. (44) was not cited in the article. The citation has now been inserted in the Results, mRNA vaccine encoding H10 induces protective levels of antibodies, paragraph two and should read:
“All animals induced neutralizing antibody titers against HA above the accepted level of protection for seasonal influenza vaccination, as measured by hemagglutination inhibition assay (HAI) (Figure 1C) as we have reported earlier (25, 44). Although some of the animals in the ID group already showed titers at the protective level after the prime immunization, all groups had titers that exceeded this level following boost. The antibody levels persisted above this level for the remainder of the study. The titers were significantly higher in the ID group compared to the IM groups for up to 2 weeks following boost, but were similar thereafter. The GLA group did not show higher HAI titers compared to the other groups, thus indicating that the mRNA/LNP formulation itself was sufficiently immunogenic. The third immunization in the GLA group resulted in a transient increase in HAI titers, which returned to similar levels as the other groups 5 weeks later.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.
References
25. Trombetta CM, Perini D, Mather S, Temperton N, Montomoli E. Overview of serological techniques for influenza vaccine evaluation: past, present and future. Vaccines (Basel) (2014) 2:707–34. doi: 10.3390/vaccines2040707
Keywords: mRNA vaccine, adaptive immune responses, non-human primates, influenza, T follicular helper cells, germinal centers
Citation: Lindgren G, Ols S, Liang F, Thompson EA, Lin A, Hellgren F, Bahl K, John S, Yuzhakov O, Hassett KJ, Brito LA, Salter H, Ciaramella G and Loré K (2019) Corrigendum: Induction of Robust B Cell Responses After Influenza mRNA Vaccination Is Accompanied by Circulating Hemagglutinin-Specific ICOS+ PD-1+ CXCR3+ T Follicular Helper Cells. Front. Immunol. 10:614. doi: 10.3389/fimmu.2019.00614
Received: 21 February 2019; Accepted: 07 March 2019;
Published: 02 April 2019.
Approved by:
Frontiers in Immunology Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2019 Lindgren, Ols, Liang, Thompson, Lin, Hellgren, Bahl, John, Yuzhakov, Hassett, Brito, Salter, Ciaramella and Loré. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Karin Loré, a2FyaW4ubG9yZUBraS5zZQ==